UCB (BRSE:UNC) - Aktienkurs, Nachrichten und Analyse

UNC Aktienübersicht

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. Mehr Details

UNC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	4/6
Vergangene Leistung	2/6
Finanzielle Gesundheit	4/6
Dividenden	4/6

Belohnungen

46.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 24.84% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Die Gewinnspannen (7.7%) sind niedriger als im Vorjahr (18.3%)

UCB SA Wettbewerber

Dottikon ES Holding

SWX:DESN

CHF 3.3b

Novartis

SWX:NOVN

CHF 183.8b

Roche Holding

SWX:ROG

CHF 204.1b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für UCB
Historische Aktienkurse
Aktueller Aktienkurs	€77.91
52-Wochen-Hoch	€0
52-Wochen-Tief	€0
Beta	0.33
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	-13.69%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	UNC	CH Pharmaceuticals	CH Markt
7D	0%	0.6%	0.5%
1Y	n/a	8.5%	6.3%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie UNC im Vergleich zur Branche Swiss Pharmaceuticals abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie UNC im Vergleich zum Swiss Markt abgeschnitten hat.

Preisvolatilität

Is UNC's price volatile compared to industry and market?
UNC volatility
UNC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	2.8%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.8%
10% least volatile stocks in CH Market	1.6%

Stabiler Aktienkurs: UNC hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von UNC im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1925	8,406	Jean-Christophe Tellier	www.ucb.com

UCB SA's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von UCB im Vergleich zum Marktanteil des Unternehmens?
UNC grundlegende Statistiken
Marktanteil	CHF 16.10b
Gewinn(TTM)	CHF 414.50m
Umsatz(TTM)	CHF 5.38b

38.8x

Kurs-Gewinn-Verhältnis

3.0x

Kurs-Umsatz-Verhältnis

Ist UNC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
UNC Gewinn- und Verlustrechnung (TTM)
Einnahmen	€5.45b
Kosten der Einnahmen	€1.67b
Bruttogewinn	€3.77b
Sonstige Ausgaben	€3.35b
Umsatz	€420.00m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	2.22
Bruttomarge	69.27%
Nettogewinnspanne	7.71%
Schulden/Eigenkapital-Verhältnis	30.5%

Wie hat sich UNC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.5%

Aktuelle Dividendenrendite

60%

Ausschüttungsquote

Zahlt UNC eine zuverlässige Dividende?

Siehe UNC Dividendenhistorie und Benchmarks

Bis wann müssen Sie UNC kaufen, um eine kommende Dividende zu erhalten?
UCB Dividendentermine
Ex-Dividenden Datum	Apr 28 2023
Datum der Dividendenzahlung	May 03 2023
Tage bis Ex-Dividende	579 days
Tage bis zum Datum der Dividendenzahlung	574 days

Zahlt UNC eine zuverlässige Dividende?

Siehe UNC Dividendenhistorie und Benchmarks

UNC Aktienübersicht

Belohnungen

Risikoanalyse

UCB SA Wettbewerber

SWX:DESN

CHF 3.3b

SWX:NOVN

CHF 183.8b

SWX:ROG

CHF 204.1b

SWX:COPN

CHF 1.0b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

Investor sentiment deteriorated over the past week

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results